All In Biotech

Drug Trial Radar · NCT03738917

Effectiveness of Antitussives, Anticholinergics and Honey Versus Usual Care in Adults With Acute Bronchitis.

Effectiveness of Antitussives, Anticholinergics and Honey Versus Usual Care in Adults With Uncomplicated Acute Bronchitis.

Last checked: Nov 19, 2026Latest source record: Aug 30, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 668 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

668

Actual

Start

Feb 1, 2019

Primary completion

Nov 30, 2021

Study completion Dec 31, 2021

Sponsor

Sponsor type
Academic, hospital or other
Collaborators
Spanish Clinical Research Network - SCReN
First posted
Nov 13, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study, which is aimed at comparing the effectiveness of 3 symptomatic therapies (dextromethorphan, ipratropium and honey) associated with usual care and the usual care in adults with acute bronchitis, is a multicentre, pragmatic, parallel group, open randomised trial. Patients aged 18 or over with uncomplicated acute bronchitis, with cough \<3 weeks as the main symptom, scoring ≥ 4 in either daytime or nocturnal cough on a 7-point Likert scale, will be randomised to one of the 4 groups. Sample: 668 patients. The primary outcome will be the number of days with moderate-severe cough.

Conditions

  • Acute Bronchitis

Interventions

  • Dextromethorphan 15 milligramsDrug

    This drug is already marketed, and therefore, the manufacturer is responsible for the elaboration and control of samples. This study drug will be provided free to the participants by the sponsor.

  • Ipratropium Bromide 20Micrograms InhalerDrug

    This drug is already marketed, and therefore, the manufacturer is responsible for the elaboration and control of samples. This study drug will be provided free to the participants by the sponsor.

  • Honey 30 g (full tablespoon)Dietary supplement

    This study product will be provided free to the participants by the sponsor.

  • Usual clinical practiceOther

    Clinicians will not be allowed to prescribe antitussives, including codeine, anticholinergic inhalers and they will not be allowed to recommend the use of honey.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Duration of moderate-severe cough in days in the four arms.Time frame: Day 29.

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Nova Lloreda Health Center

    Badalona, Catalonia, Spain

  • Martí i Julià Health Center

    Badalona, Catalonia, Spain

  • Balaguer Health Center

    Balaguer, Catalonia, Spain

  • Via Roma Health Centre

    Barcelona, Catalonia, Spain

  • La Marina Health Center

    Barcelona, Catalonia, Spain

  • CAP Passeig Maragall (EAP Camp de l'Arpa)

    Barcelona, Catalonia, Spain

  • Cornellà - La Gavarra Health Center

    Cornellà de Llobregat, Catalonia, Spain

  • Pineda de Mar Health Center

    Pineda de Mar, Catalonia, Spain

  • Ca n'OriacHealth Center

    Sabadell, Catalonia, Spain

  • Molí Nou Health Center

    Sant Boi de Llobregat, Catalonia, Spain

  • Singuerlin Health Center

    Santa Coloma de Gramenet, Catalonia, Spain

  • CAP Jaume I

    Tarragona, Catalonia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.